Free Trial

Co-Diagnostics Q3 2024 Earnings Report

Co-Diagnostics logo
$0.75 -0.04 (-4.94%)
As of 01/31/2025 04:00 PM Eastern

Co-Diagnostics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.01
One Year Ago EPS
-$0.20

Co-Diagnostics Revenue Results

Actual Revenue
$0.64 million
Expected Revenue
$0.40 million
Beat/Miss
Beat by +$240.00 thousand
YoY Revenue Growth
N/A

Co-Diagnostics Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Conference Call Resources

Co-Diagnostics Earnings Headlines

You won’t believe where OpenAI billionaire is investing now
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.
Co-Diagnostics Reports Q3 2024 Financial Results
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Co-Diagnostics Profile

More Earnings Resources from MarketBeat